Fresh2 Group Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRES research report →
Companyfresh2.co
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution.
- CEO
- Haohan Xu
- IPO
- 2020
- Employees
- 75
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $2.08M
- P/E
- -0.00
- P/S
- 1.18
- P/B
- -0.00
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 69.21%
- Op Margin
- -870.20%
- Net Margin
- -846.01%
- ROE
- 1121.57%
- ROIC
- -2573.82%
Growth & Income
- Revenue
- $12.04M · -32.16%
- Net Income
- $-101,893,000 · 13.03%
- EPS
- $-106578.00 · 69.06%
- Op Income
- $-104,807,000
- FCF YoY
- 24.16%
Performance & Tape
- 52W High
- $9.00
- 52W Low
- $0.73
- 50D MA
- $1.06
- 200D MA
- $2.29
- Beta
- 1.28
- Avg Volume
- 17.45K
Get TickerSpark's AI analysis on FRES
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 1, 24 | Liang Zhijun | other | 0 |
| Mar 11, 24 | Zhao Zhigang | other | 100,000 |
| Apr 14, 25 | Li Xiaoyu | other | 471,695 |
| Mar 11, 24 | Pu Tianruo | other | 100,000 |
| Mar 11, 24 | Tian Honggang | other | 100,000 |
| Jan 1, 24 | Xu Haohan | other | 0 |
| Jan 1, 24 | Xu Haohan | other | 0 |
Our FRES Coverage
We haven't published any research on FRES yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FRES Report →